HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R E Schreck Selected Research

SU11925

12/2001High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R E Schreck Research Topics

Disease

2Neoplasms (Cancer)
12/2001 - 12/2000
1Carcinoma (Carcinomatosis)
12/2001
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2001

Drug/Important Bio-Agent (IBA)

1SU11925IBA
12/2001
1Epidermal Growth Factor (EGF)IBA
12/2001
1Phosphotransferases (Kinase)IBA
12/2001
1ErbB Receptors (EGF Receptor)IBA
12/2001
1Tyrosine (L-Tyrosine)FDA Link
12/2001
1Semaxinib (SU5416)IBA
12/2000
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
12/2000
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2000
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2000